<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277549</url>
  </required_header>
  <id_info>
    <org_study_id>BCT10-03</org_study_id>
    <nct_id>NCT01277549</nct_id>
  </id_info>
  <brief_title>Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors</brief_title>
  <official_title>Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood Center of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LeukoLab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra
      Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of
      differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy
      G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mononuclear Cell Collection Efficiency</measure>
    <time_frame>One day</time_frame>
    <description>The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD34+ Cell Collection Efficiency</measure>
    <time_frame>one day</time_frame>
    <description>The collection efficiency for CD34+ cells is defined as the percent of processed CD34+ cells that were in fact collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Collection Efficiency</measure>
    <time_frame>One Day</time_frame>
    <description>Platelet contamination of the cell product was measured as the platelet collection efficiency, that is, as the percent of platelets processed that were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit of MNC Product</measure>
    <time_frame>One Day</time_frame>
    <description>The hematocrit of the collected product was used to quantitate RBC (red blood cell) contamination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Granulocyte % of MNC Product</measure>
    <time_frame>One day</time_frame>
    <description>Granulocyte contamination of the MNC product was quantitated as the percent of total product WBC (white blood cell) that were segmented granulocytes or bands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viability of the Collected MNC Product</measure>
    <time_frame>One day</time_frame>
    <description>The viability of the collected white blood cells was assessed using the 7-AAD (7-amino actinomycin D) viability dye in a flow cytometric assay. Viability assessment is incorporated into the CD34 assay. This assay was only performed on G-CSF mobilized donors as nonmobilized donor have too few CD34+ cells to detect. Thus viability of the collected WBCs is reported only for the G-CSF mobilized arm.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">71</enrollment>
  <condition>Leukapheresis</condition>
  <arm_group>
    <arm_group_label>Non-mobilized donors</arm_group_label>
    <description>In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF mobilized donors</arm_group_label>
    <description>In this arm the collection efficiency of CD34+ cells will be studied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mononuclear cell collection.</intervention_name>
    <description>Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.</description>
    <arm_group_label>Non-mobilized donors</arm_group_label>
    <arm_group_label>G-CSF mobilized donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Community Volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acceptable health history to allow blood product collection

          -  Weight &gt;50&lt;125 Kg (kilogram).

          -  Male or non-pregnant, non-nursing female.

          -  General good health, as determined by questionnaire.

          -  Normal prescreening complete blood count.

          -  Platelet count&gt;150 x 10^3/uL (microliter) at initial screening and &gt;120 x 10^3/uL
             immediately prior to leukapheresis.

          -  Adequate peripheral venous access to allow collection of product.

          -  Able to read, understand, and sign the informed consent form. Additional Inclusion
             Criteria for Mobilized Subjects

          -  If male, be willing to use a condom during sexual relations with a female partner
             until 48 hours following the last G-CSF injection.

          -  If female and of childbearing potential, be willing to use a medically acceptable
             contraceptive until 48 hours following the last G-CSF injection.

        Exclusion Criteria:

          -  a) Collection or loss of:

               -  more than a ½ pint (1 cup) of whole blood within the prior 56 days or,

               -  more than 3 L (liter) of whole blood or 1.5 L of red blood cells within the prior
                  12 months or,

               -  more than 12 L of plasma within the prior 12 months or,

               -  a leukapheresis within the prior six weeks or,

               -  a plateletpheresis within the prior 48 hours or two within the prior 7 days or
                  twenty-four within the last 12 months or,

               -  a plasmapheresis within the prior 48 hours or two within the prior 7 days.

          -  Acute or symptomatic chronic lung disease.

          -  Active or chronic heart disease, including hypertension controlled by medication.

          -  History of hematologic malignancy or chronic hematologic disorder or bleeding
             disorder.

          -  Reactive test indicative of infection with T. pallidum, Human T-lymphotropic virus,
             HIV, Hepatitis C Virus, or Hepatitis B Virus (except isolated Hepatitis B Core
             Antibody Reactivity.

          -  Presence of psychological traits or physiological or medical conditions that would
             make subject unlikely to tolerate the procedures.

          -  Subjects taking prescription medications other than those deemed allowable by the
             investigator.

          -  Abnormal serum electrolytes or serum calcium levels.

          -  Abnormal serum creatinine level.

          -  Abnormal liver function results on ALT (alanine amino transferase) test.

          -  Abnormal coagulation testing on prothrombin time or partial thromboplastin time.

          -  Inadequate antecubital veins for leukapheresis or inability or unwillingness to
             tolerate leukapheresis.

          -  If female, pregnant or lactating. Additional Exclusion Criteria for Mobilized Subjects

          -  Received a G-CSF injection in the prior 4 months, or received more than twenty-five
             (25) doses of G-CSF (a dose includes several individual injections administered on one
             occasion).

          -  Known hypersensitivity to G-CSF or any E. coli-derived products.

          -  History of autoimmune condition or disorder, unless approved by principal
             investigator.

          -  Immediate family history (parents, grandparents, siblings, children) of hematologic
             malignancy.

          -  Active or history of iritis (anterior uveitis) or episcleritis.

          -  History of deep vein thrombosis or pulmonary embolism.

          -  Current treatment with lithium.

          -  Spleen tip palpable during physical exam.

          -  Positive SickleDex test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome R Bill, MD</last_name>
    <role>Study Director</role>
    <affiliation>Terumo BCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leukolab/Allcells</name>
      <address>
        <city>Emeryville</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Key Biologics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104-3401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <results_first_submitted>September 11, 2012</results_first_submitted>
  <results_first_submitted_qc>May 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukapheresis</keyword>
  <keyword>Hematopoetic Stem Cell Mobilization</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult donors were recruited at three blood collection centers to undergo a mononuclear cell collection using the experimental device, between January and September, 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>G-CSF Mobilized Donors</title>
          <description>In this arm the donors received G-CSF (granulocyte colony stimulating factor) prior to the MNC (mononuclear cell) collection. G-CSF causes the mobilization of hematopoetic stem cells which are CD34 (cluster of differentiation 34) + to the peripheral blood. Collection efficiency of all mononuclear cells and of the CD34+ subset of mononuclear cells was assessed.</description>
        </group>
        <group group_id="P2">
          <title>Non-mobilized Donors</title>
          <description>In this arm, donors were not mobilized prior to mononuclear cell collection. Only collection efficiency of mononuclear cells could be assessed as CD34+ cells are not present in this population.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data is given only for subjects who completed the study. Reasons why subjects did not complete the study are given above in Participant Flow.</population>
      <group_list>
        <group group_id="B1">
          <title>G-CSF Mobilized Donors</title>
          <description>Donors received G-CSF prior to MNC collection</description>
        </group>
        <group group_id="B2">
          <title>Nonmobilized Donors</title>
          <description>Donors not mobilized prior to MNC collection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Median and range reported are for donors who completed the study.</description>
          <units>Years of Age</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="19" upper_limit="45"/>
                    <measurement group_id="B2" value="33" lower_limit="29" upper_limit="47"/>
                    <measurement group_id="B3" value="31" lower_limit="19" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mononuclear Cell Collection Efficiency</title>
        <description>The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.</description>
        <time_frame>One day</time_frame>
        <population>Results are given for all per protocol subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>Donors received G-CSF prior to MNC collection.</description>
          </group>
          <group group_id="O2">
            <title>Nonmobilized Donors</title>
            <description>Donors were not mobilized prior to MNC collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Mononuclear Cell Collection Efficiency</title>
          <description>The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.</description>
          <population>Results are given for all per protocol subjects.</population>
          <units>% of processed MNCs that were collected</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="17" upper_limit="147"/>
                    <measurement group_id="O2" value="57" lower_limit="27" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Collection Efficiency</title>
        <description>Platelet contamination of the cell product was measured as the platelet collection efficiency, that is, as the percent of platelets processed that were collected.</description>
        <time_frame>One Day</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>In this arm, donors were mobilized with G-CSF prior to collection.</description>
          </group>
          <group group_id="O2">
            <title>Nonmobilized Donors</title>
            <description>In this arm, donors were not mobilized prior to collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Collection Efficiency</title>
          <description>Platelet contamination of the cell product was measured as the platelet collection efficiency, that is, as the percent of platelets processed that were collected.</description>
          <population>Per protocol</population>
          <units>% of processed platelets collected</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12" upper_limit="47"/>
                    <measurement group_id="O2" value="12" lower_limit="5" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit of MNC Product</title>
        <description>The hematocrit of the collected product was used to quantitate RBC (red blood cell) contamination.</description>
        <time_frame>One Day</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>In this arm, donors were mobilized with G-CSF prior to collection.</description>
          </group>
          <group group_id="O2">
            <title>Nonmobilized Donors</title>
            <description>In this arm, donors were not mobilized prior to collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit of MNC Product</title>
          <description>The hematocrit of the collected product was used to quantitate RBC (red blood cell) contamination.</description>
          <population>Per protocol</population>
          <units>RBC % of product volume</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.4" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Granulocyte % of MNC Product</title>
        <description>Granulocyte contamination of the MNC product was quantitated as the percent of total product WBC (white blood cell) that were segmented granulocytes or bands.</description>
        <time_frame>One day</time_frame>
        <population>Results given for all per protocol subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>In this arm, donors were mobilized with G-CSF prior to collection.</description>
          </group>
          <group group_id="O2">
            <title>Nonmobilized Donors</title>
            <description>In this arm, donors were not mobilized prior to collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Granulocyte % of MNC Product</title>
          <description>Granulocyte contamination of the MNC product was quantitated as the percent of total product WBC (white blood cell) that were segmented granulocytes or bands.</description>
          <population>Results given for all per protocol subjects.</population>
          <units>percentage of WBCs collected</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="0.0" upper_limit="48"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viability of the Collected MNC Product</title>
        <description>The viability of the collected white blood cells was assessed using the 7-AAD (7-amino actinomycin D) viability dye in a flow cytometric assay. Viability assessment is incorporated into the CD34 assay. This assay was only performed on G-CSF mobilized donors as nonmobilized donor have too few CD34+ cells to detect. Thus viability of the collected WBCs is reported only for the G-CSF mobilized arm.</description>
        <time_frame>One day</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>Donors received G-CSF prior to MNC collection</description>
          </group>
        </group_list>
        <measure>
          <title>Viability of the Collected MNC Product</title>
          <description>The viability of the collected white blood cells was assessed using the 7-AAD (7-amino actinomycin D) viability dye in a flow cytometric assay. Viability assessment is incorporated into the CD34 assay. This assay was only performed on G-CSF mobilized donors as nonmobilized donor have too few CD34+ cells to detect. Thus viability of the collected WBCs is reported only for the G-CSF mobilized arm.</description>
          <population>Per Protocol</population>
          <units>percentage of total WBCs collected</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD34+ Cell Collection Efficiency</title>
        <description>The collection efficiency for CD34+ cells is defined as the percent of processed CD34+ cells that were in fact collected.</description>
        <time_frame>one day</time_frame>
        <population>Results are given for all per protocol subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Mobilized Donors</title>
            <description>Donors received G-CSF prior to MNC collection.</description>
          </group>
        </group_list>
        <measure>
          <title>CD34+ Cell Collection Efficiency</title>
          <description>The collection efficiency for CD34+ cells is defined as the percent of processed CD34+ cells that were in fact collected.</description>
          <population>Results are given for all per protocol subjects.</population>
          <units>% of processed CD34+ cells collected</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="43" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the Nonmobilized Arm, adverse events were collected during the leukapheresis procedure itself and for one week following the procedure. For the G-CSF mobilized arm, adverse events were also collected during the 5 days of mobilization.</time_frame>
      <desc>All subjects who underwent a leukapheresis procedure were included in the adverse event analysis. This includes the categories &quot;COMPLETED&quot; and &quot;NOT COMPLETED--Protocol Violation&quot; on the Participant Flow section above. Thus 15+10=25 Mobilized and 15+1+16 Nonmobilized subjects are included for a total of 41 subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>G-CSF Mobilized Donors</title>
          <description>Donors received G-CSF prior to MNC collection</description>
        </group>
        <group group_id="E2">
          <title>Nonmobilized Donors</title>
          <description>Donors not mobilized prior to MNC collection. Note that some Adverse Events (Flu-like symptoms, Muscle Aches, and Bone Pain) apply only to G-CSF mobilized donors. Nonmobilized donors were not assessed for these adverse events as they were not &quot;at risk&quot;.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arm numbness/stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Citrate reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Venous infiltration/hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerome R Bill, M.D.</name_or_title>
      <organization>Terumo BCT</organization>
      <phone>303-231-4729</phone>
      <email>jerry.bill@terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

